Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Hadaschik

Showing results (221-230 of 232) with videos related to

Pageof 24
Sort By:
European Urology Oncology|April 25, 2024
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP StudyRonan Flippot, Tugce Telli, Maud Velev, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 15, 2025
The German Cancer Consortium (DKTK) multi-center prospective phase 1/2 <sup>68</sup>Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic accuracy compared to histopathology and their impact on patient managementFrederik L Giesel, Stefan A Koerber, Boris Hadaschik, et al.
European Urology|September 13, 2025
SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi AnalysisKen Herrmann, Jochen Walz, Steven MacLennan, et al.
Cell Reports. Medicine|January 19, 2024
Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donorsFrancesca Pettinella, Barbara Mariotti, Chiara Lattanzi, et al.
NPJ Digital Medicine|October 14, 2025
Leveraging Sarcopenia index by automated CT body composition analysis for pan cancer prognostic stratificationKatarzyna Borys, Johannes Haubold, Julius Keyl, et al.
Scientific Reports|November 14, 2018
Correlation between genomic index lesions and mpMRI and <sup>68</sup>Ga-PSMA-PET/CT imaging features in primary prostate cancerClaudia Kesch, Jan-Philipp Radtke, Axel Wintsche, et al.
Nature Cancer|January 30, 2025
Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligenceJulius Keyl, Philipp Keyl, Grégoire Montavon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2026
Salvage Radiotherapy Confers an Overall Survival Advantage in Biochemical Recurrence of Prostate Cancer: Evidence from the International PROMISE RegistryNika Guberina, Madeleine J Karpinski, Maja Guberina, et al.
Urologie (Heidelberg, Germany)|September 25, 2023
[Urinary incontinence after radical prostatectomy for prostate cancer-data from 17,149 patients from 125 certified centers]Christoph Kowalski, Nora Tabea Sibert, Peter Hammerer, et al.
European Journal of Epidemiology|April 5, 2023
Profile of the multicenter cohort of the German Cancer Consortium's Clinical Communication PlatformDaniel Maier, Jörg Janne Vehreschild, Barbara Uhl, et al.
Pageof 24

Showing results (221-230 of 232) with videos related to

Sort By:
Pageof 24
European Urology Oncology|April 25, 2024
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP StudyRonan Flippot, Tugce Telli, Maud Velev, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 15, 2025
The German Cancer Consortium (DKTK) multi-center prospective phase 1/2 <sup>68</sup>Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic accuracy compared to histopathology and their impact on patient managementFrederik L Giesel, Stefan A Koerber, Boris Hadaschik, et al.
European Urology|September 13, 2025
SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi AnalysisKen Herrmann, Jochen Walz, Steven MacLennan, et al.
Cell Reports. Medicine|January 19, 2024
Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donorsFrancesca Pettinella, Barbara Mariotti, Chiara Lattanzi, et al.
NPJ Digital Medicine|October 14, 2025
Leveraging Sarcopenia index by automated CT body composition analysis for pan cancer prognostic stratificationKatarzyna Borys, Johannes Haubold, Julius Keyl, et al.
Scientific Reports|November 14, 2018
Correlation between genomic index lesions and mpMRI and <sup>68</sup>Ga-PSMA-PET/CT imaging features in primary prostate cancerClaudia Kesch, Jan-Philipp Radtke, Axel Wintsche, et al.
Nature Cancer|January 30, 2025
Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligenceJulius Keyl, Philipp Keyl, Grégoire Montavon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2026
Salvage Radiotherapy Confers an Overall Survival Advantage in Biochemical Recurrence of Prostate Cancer: Evidence from the International PROMISE RegistryNika Guberina, Madeleine J Karpinski, Maja Guberina, et al.
Urologie (Heidelberg, Germany)|September 25, 2023
[Urinary incontinence after radical prostatectomy for prostate cancer-data from 17,149 patients from 125 certified centers]Christoph Kowalski, Nora Tabea Sibert, Peter Hammerer, et al.
European Journal of Epidemiology|April 5, 2023
Profile of the multicenter cohort of the German Cancer Consortium's Clinical Communication PlatformDaniel Maier, Jörg Janne Vehreschild, Barbara Uhl, et al.
Pageof 24